Does teplizumab (Tzield) only delay the onset of type 1 diabetes rather than prevent it?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Teplizumab Delays But Does Not Prevent Type 1 Diabetes

Yes, teplizumab only delays the onset of stage 3 type 1 diabetes—it does not prevent it. The drug extends the median time to symptomatic diabetes from 24.4 months to 48.4 months (a 2-year delay), but the majority of treated patients still eventually progress to clinical disease 1.

The Evidence on Delay vs. Prevention

The FDA-approved indication explicitly states teplizumab is used "to delay the onset of Stage 3 type 1 diabetes"—not to prevent it 2. This distinction is critical and based on the pivotal trial data:

  • 43% of teplizumab-treated patients (19/44) still developed stage 3 diabetes during the study period
  • 72% of placebo patients (23/32) developed stage 3 diabetes
  • The hazard ratio of 0.41 demonstrates delayed progression, not disease prevention 1

What This Means Clinically

Teplizumab buys time, not a cure. The 2-year median delay represents:

  • Extended preservation of beta-cell function during the presymptomatic period
  • Postponement of insulin dependence and its associated burdens
  • Potential reduction in diabetic ketoacidosis risk at diagnosis (as high-risk individuals are monitored closely) 3

However, the autoimmune destruction of pancreatic beta-cells continues. The drug modulates the immune response temporarily through CD3-directed T-cell effects, but does not eliminate the underlying autoimmunity 1.

Duration of Benefit and Long-Term Outcomes

The current evidence shows:

  • Median delay of approximately 24 months between treatment and placebo groups
  • No data demonstrating permanent prevention of stage 3 diabetes
  • Ongoing clinical trials are investigating methods to extend this benefit or achieve true prevention 1

Multiple guidelines acknowledge that while teplizumab represents a breakthrough as the first disease-modifying therapy for type 1 diabetes, it remains a delaying strategy rather than a preventive cure 3.

Predictors of Response

Certain genetic and immunologic factors predict better response to teplizumab (longer delay):

  • Presence of HLA-DR4: HR 0.20 for progression
  • Absence of HLA-DR3: HR 0.18 for progression
  • Absence of anti-zinc transporter 8 antibody: HR 0.07 for progression 1

Even in these favorable subgroups, the outcome is extended delay, not prevention.

Clinical Counseling Points

When discussing teplizumab with eligible patients (age ≥8 years with stage 2 type 1 diabetes):

  • Set realistic expectations: Emphasize this delays, not prevents, diabetes onset
  • Quantify the benefit: Approximately 2 years of additional time before insulin dependence
  • Acknowledge uncertainty: Individual response varies; some may progress sooner, others later
  • Discuss trade-offs: 14-day infusion course with transient lymphopenia (73%) and rash (36%) for a median 2-year delay 1

The Broader Context

The 2023 and 2025 ADA guidelines frame teplizumab as part of an evolving landscape where "numerous clinical studies are being conducted to test methods for preventing or delaying the onset of stage 3 type 1 diabetes" 1. The language consistently distinguishes between "prevention" (not yet achieved) and "delay" (what teplizumab accomplishes).

The bottom line: Teplizumab represents a paradigm shift in type 1 diabetes management by offering the first opportunity to intervene before symptoms appear, but it postpones rather than prevents the inevitable progression to clinical disease in most patients.

References

Related Questions

Do anti‑rejection (immunosuppressive) drugs affect insulin metabolism or glucose control in patients with type 1 diabetes?
In a 38-year-old patient with a ventricular septal defect and an unspecified cardiac murmur who now has progressive erythrocytosis (elevated red blood cell count, hemoglobin, and hematocrit), an LDL cholesterol of 145 mg/dL, and an HbA1c of 5.8 % (prediabetes), what is the appropriate next step in management?
In a 36-year-old male with left S1 radiculopathy (sluggish left ankle jerk, difficulty walking on toes on the left, no motor weakness on the Medical Research Council scale) and MRI of the lumbar spine showing left paracentral disc herniation at L5‑S1 with lateral recess compression of the left S1 traversing root, what dose and duration of injectable dexamethasone and subsequent oral methylprednisolone should be prescribed?
A patient with Graves disease on methimazole 10 mg twice daily presents three weeks later with a generalized rash and thyroid labs that have improved but remain elevated; what is the next step in management?
What is the recommended general anesthesia regimen, including drug selection and dose adjustments, for a patient with liver cirrhosis?
Why does a chronic arteriovenous (AV) fistula for hemodialysis cause enlargement and varicosities, and what is the appropriate management?
What are the causes, diagnostic workup, and treatment options for leukoencephalopathy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.